Germline Variants Linked to Increased Cancer Risk in Pediatric Patients

Illuminating Genetic Links to Childhood Cancer Risk

While cancer affects millions of Americans [1], pediatric malignancies present distinct clinical challenges [2]. Genetic testing is increasingly used in children for a wide range of non-cancerous indications, such as developmental delay or immune dysfunction, often uncovering incidental genetic variants. However, the specific future cancer risk conferred by these incidental findings has been poorly quantified. A large-scale analysis of pediatric exome data now provides much-needed clarity on the association between certain germline variants and the subsequent development of childhood cancer, offering a more defined framework for risk stratification. The study's findings are situated within a broader context of research on factors influencing long-term health, such as adverse childhood experiences [3] and the global prevalence of conditions like autism [4].

Large-Scale Genetic Screening Identifies Cancer Predisposition

A recent investigation offers a detailed look into the genetic landscape of cancer predisposition by analyzing data from a cohort of 75,602 pediatric patients. These children were referred for exome sequencing, a technique that analyzes the protein-coding regions of the genome, between January 2016 and January 2025. While the primary reasons for testing were often neurological, metabolic, or immunological symptoms, the researchers leveraged this vast dataset to systematically screen for variants in 139 known tumor susceptibility genes. This secondary analysis of 110,692 variants identified 501 variants (0.45%) classified as pathogenic or likely pathogenic (P/LP), meaning they are strongly associated with disease. These included 456 single-nucleotide variants (changes to a single DNA base pair) and 45 copy number variations (deletions or duplications of larger DNA segments). An additional 3,848 variants (3.5%) were categorized as variants of uncertain significance leaning toward likely pathogenic, a classification for which evidence is still accumulating.

Germline Variants in Tumor-Bearing Pediatric Patients

To understand the contribution of germline genetics to existing disease, the researchers focused on the 411 patients in the cohort who had tumors. This group included 203 patients with preexisting tumors at the time of testing and 208 who developed tumors during follow-up, demonstrating the dual utility of genetic data for both diagnosis and prognosis. Within this tumor-bearing subgroup, a notable 32.6% (134 patients) harbored causative germline P/LP variants. The analysis pinpointed specific genes responsible for this predisposition. The most common were NF1 (13.1% of patients), associated with neurofibromatosis; TSC2 (5.8%), linked to tuberous sclerosis complex; RB1 (4.6%), known for its role in retinoblastoma; and WT1 (3.2%), associated with Wilms tumor. These findings confirm that a substantial fraction of pediatric tumors, even when not initially suspected to be hereditary, are driven by identifiable, inherited genetic variants.

Quantifying Future Cancer Risk in Variant Carriers

Perhaps the most clinically significant aspect of the study was its prospective quantification of future cancer risk. The authors followed 64,187 patients who were initially tumor-free to determine how different variant types influenced the development of new malignancies. The results revealed a stark difference in outcomes. Children carrying P/LP germline variants had a malignant tumor incidence of 3.23 per 1,000 person-years. This rate, which translates to approximately three new cancers per year for every 1,000 children with these variants, was more than ten times higher than in other groups. For comparison, the incidence was just 0.236 per 1,000 person-years for children with variants of uncertain significance leaning toward likely pathogenic and 0.272 per 1,000 person-years for those with other variants. This robust statistical evidence provides a clear measure of the elevated cancer risk conferred by P/LP variants found incidentally in pediatric patients.

Clinical Implications for Genetic Counseling and Surveillance

The findings from this large cohort provide an actionable evidence base for clinicians managing pediatric patients who undergo genetic testing. The discovery of a P/LP variant in a tumor susceptibility gene, even when testing was ordered for an unrelated reason like developmental delay, should no longer be viewed as a finding of uncertain consequence. The data strongly suggest that such a result warrants proactive clinical management. Specifically, the more than tenfold increase in malignant tumor incidence (3.23 vs. ~0.25 per 1,000 person-years) associated with P/LP variants provides a clear rationale for initiating genetic counseling and implementing a structured surveillance plan. For the practicing physician, this means that identifying a P/LP variant in genes like NF1, TSC2, or RB1 should trigger a referral for specialized monitoring, tailored to the risks associated with that specific gene, with the goal of facilitating earlier detection and intervention for any subsequent malignancy.

References

1. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA A Cancer Journal for Clinicians. 2019. doi:10.3322/caac.21565

2. Patel P, Sing EPC, Dupuis LL. Safety of clinical practice guideline-recommended antiemetic agents for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric patients: a systematic review and meta-analysis.. Expert opinion on drug safety. 2019. doi:10.1080/14740338.2019.1568988

3. Hughes K, Bellis MA, Hardcastle KA, et al. The effect of multiple adverse childhood experiences on health: a systematic review and meta-analysis. The Lancet Public Health. 2017. doi:10.1016/s2468-2667(17)30118-4

4. Zeidan J, Fombonne É, Scorah J, et al. Global prevalence of autism: A systematic review update. Autism Research. 2022. doi:10.1002/aur.2696